EGFR News

News

PD-L1 Score Demonstrates Value as Prognostic Biomarker in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

01/18/2023

Derek Cowsert

Study finds PD-L1 scores exhibit value in predicting survival rates in patients with early stage EFGR-mutated non-small cell lung cancer.

Study finds PD-L1 scores exhibit...

01/18/2023

Oncology

News

Somatic Missense Mutations Identified as Promising Targets of Future Treatment for NSCLC

08/29/2022

Derek Cowsert

Study findings reveal 4 somatic missense mutations as rare genetic markers for NSCLC, making them promising targets for study and development of future treatments.

Study findings reveal 4 somatic...

08/29/2022

Oncology

News

TP53 Alterations Predict Rapid Treatment Resistant Evolution in Patients With EFGR-Mutated NSCLC

08/09/2022

Derek Cowsert

Study findings reveal TP53 alterations were associated with rapid progression of treatment resistance evolution regardless of treatment mechanism in patients with EFGR-mutated NSCLC.

Study findings reveal TP53...

08/09/2022

Oncology

News

Amivantamab Associated With Improved Outcomes vs Real-World Therapies in EGFR-Mutated NSCLC

07/07/2022

Janelle Bradley

Among patients with EGFR-mutated advanced NSCLC whose disease progressed after platinum-based chemotherapy, treatment with amivantamab is associated with improved outcomes vs real-world therapies, according to a recent study.

Among patients with EGFR-mutated...

07/07/2022

Oncology

News

Aumolertinib vs Gefitinib as First-Line Treatment for Patients With EFGR-Mutated NSCLC

07/06/2022

Derek Cowsert

Study findings reveal first-line treatment with aumolertinib was associated with improved survival outcomes compared to gefitinib in patients with EFGR-mutated NSCLC.

Study findings reveal first-line...

07/06/2022

Oncology

News

First-Line Bevacizumab Plus Erlotinib Prolongs PFS in EGFR-Mutated Advanced NSCLC: BEVERLY Trial

06/20/2022

Yvette C. Terrie, BSPharm, RPh

Yvette C. Terrie, BSPharm, RPh ...

Bevacizumab added to erlotinib improved PFS among Italian patients with EGFR-mutated NSCLC, according to results from the phase 3 BEVERLY trial.

Bevacizumab added to erlotinib...

06/20/2022

Oncology

News

Osimertinib Plus Bevacizumab Fails to Improve PFS Among Patients With NSCLC Harboring EGFR Mutations

06/20/2022

Yvette C. Terrie, BSPharm, RPh

Yvette C. Terrie, BSPharm, RPh ...

In a phase 2 study, osimertinib plus bevacizumab failed to improve PFS vs osimertinib monotherapy for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR mutations.

In a phase 2 study, osimertinib...

06/20/2022

Oncology

News

First-Line Treatment With TKIs Associated With Improved Survival in EGFR-Positive NSCLC

05/05/2022

John Otrompke

In the 7 years following the release of treatment guidelines recommending TKIs for EGFR-positive NSCLC, OS has almost doubled among female patients younger than 50 years, according to a population-based study from the Netherlands.

In the 7 years following the...

05/05/2022

Oncology

News

What is the Preferred Treatment Option for Patients with NSCLC Harboring Uncommon EGFR Mutations?

05/05/2022

John Otrompke

Study findings suggest EGFR TKIs are the preferred treatment option for patients with NSCLC and uncommon EGFR mutations in the real-world setting.

Study findings suggest EGFR TKIs...

05/05/2022

Oncology

News

First-Line EGFR Inhibition Improves Overall Survival in EGFR–Amplified Gastroesophageal Adenocarcinoma

05/05/2022

John Otrompke

Patients with EGFR–amplified gastroesophageal adenocarcinoma derive significant benefit from EGFR inhibition in the first-line setting, according to findings from a recent analysis.

Patients with EGFR–amplified...

05/05/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology